(Q34782224)

4 August 2017

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects (English)

1 reference

4 August 2017

1 reference

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

J P Arm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

I Bottoli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Skerjanec

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

D Floch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Groenewegen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

S Maahs

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

C E Owen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

I Jones

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

1 reference

1 November 2014

1 reference

Clinical & Experimental Allergy

4 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1371-1385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

IgE and mast cells in allergic disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

IgE in allergy and asthma today

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Evaluation of the Cohort Size in Phase I Dose Escalation Trials Based on Laboratory Data

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Humanization of an antibody directed against IgE

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FCEA.12400

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FCEA.12400

The binding site on human immunoglobulin E for its high affinity receptor.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4278557

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis

26 October 2018

1 reference

12 December 2020

Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions

1 reference

12 December 2020

Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy

1 reference

12 December 2020

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

1 reference

12 December 2020

Identifiers

DOI

10.1111/CEA.12400

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25200415%20AND%20SRC:MED&resulttype=core&format=json